Abstract:Glioblastoma multiforme (GBM) is highly aggressive and difficult to treat, necessitating the development of new therapies. Photoactivated chemotherapy (PACT) has emerged as a promising method, where biologically active compounds are “caged” into inactive prodrugs, and re-activated by visible light irradiation at the tumor site, potentially offering more patient-friendly treatments without compromising antitumor efficacy. In this study, we investigated the activity of a series of ruthenium-based PACT compounds [1](PF6)2-[3](PF6)2 in U-87MG glioblastoma cells, a common in vitro model for glioblastoma, and the safety of these compounds in SH-SY5Y cells, which is a recognized model for healthy neurons. The action of these compounds was compared to that of Donepezil, a known acetylcholinesterase inhibitor used in the treatment of brain disorders. Promising light-activated anticancer activity was observed in U-87MG cells for [3](PF6)2 while the two other compounds were inactive([1](PF6)2) or non-activated ([2](PF6)2). In non-cancerous SH-SY5Y cells the light-activated complexes surprisingly enhanced cell proliferation in a manner similar to Donepezil. While significantly higher amounts of Ru were found in SH-SY5Y cells upon green light irradiation, in particular for [3](PF6)2, this cell proliferation effect was independent from ruthenium cellular uptake. Given the importance of Ca2+ levels for the normal function of neurons, we also examined Ca2+ accumulation upon treatment with ruthenium and light. Increased Ca2+ uptake was found in cells treated with inactivated [1](PF6)2 , [2](PF6)2 , or with green light only. Upon treatment with [3](PF6)2 intracellular Ca2+ content was not changed in the dark but it significantly increased upon light activation, without observable sign of cell death. The structure-dependent action of the ruthenium compounds on Ca2+ homeostasis suggested a docking studies with the NMDA, serotonin, and AMPA receptors, which all act on calcium levels. Docking revealed that [3](PF6)2 interacts with the NMDA receptor, which might be responsible for the enhanced Ca2+ uptake upon light activation in SH-SY5Y cells. Overall, although [3](PF6)2 was phototoxic to U-87MG cells, the combination of this prodrug and green light irradiation enhanced the survival of neuronal-like cells and increased intracellular Ca2+ levels, probably via interaction with the NMDA receptor. These findings highlight the potential of ruthenium-based PACT prodrugs in treating glioblastoma cells while maintaining the viability of nearby, healthy neuronal cells

Cyclic Ruthenium-Peptide Conjugates as Integrin-Targeting Phototherapeutic Prodrugs for the Treatment of Brain Tumors

Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles.

A HCBP1 Peptide Conjugated Ruthenium Complex for Targeted Therapy of Hepatoma.

Ruthenium-Cathepsin Inhibitor Conjugates for Green Light-Activated Photodynamic Therapy and Photochemotherapy

Towards Selective Delivery of a Ruthenium(II) Polypyridyl Complex‐Containing Bombesin Conjugate into Cancer Cells

Engineering Molecular Self-Assembly of Theranostic Nanoprobes for Dual-Modal Imaging-Guided Precise Chemotherapy

A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent

Transferrin/aptamer conjugated mesoporous ruthenium nanosystem for redox-controlled and targeted chemo-photodynamic therapy of glioma.

Ruthenium Pyrazole Complexes: A Family of Highly Active Metallodrugs for Photoactivated Chemotherapy

A Second Near-Infrared Ru(II) Polypyridyl Complex for Synergistic Chemo-Photothermal Therapy

Peptide-conjugated nanoparticles for targeted photodynamic therapy

Photoactivatable Ruthenium Complexes Containing Minimal Straining Benzothiazolyl-1,2,3-triazole Chelators for Cancer Treatment

Oxygen-dependent interactions between the ruthenium cage and the photoreleased inhibitor in NAMPT-targeted photoactivated chemotherapy

A self-assembled Ru–Pt metallacage as a lysosome-targeting photosensitizer for 2-photon photodynamic therapy

Acid-Responsive Polymer Micelles for Targeted Delivery and Bioorthogonal Activation of Prodrug through Ru Catalyst in Tumor Cells

Ru(II)-Photoactive Agents for Targeting ER Stress and Immunogenic Cell Death

Lysosome Targeting Bis-terpyridine Ruthenium(II) Complexes: Photophysical Properties and in Vitro Photodynamic Therapy.

In Situ Bioconjugation of a Maleimide-Functionalized Ruthenium-Based Photosensitizer to Albumin for Photodynamic Therapy

Treatment of Glioblastoma tumors using photoactivated chemotherapy

7401 Development and Evaluation of Ruthenium-based Photoactivated Chemotherapeutic Agents

Cyclometalated Iridium(III) Complex-Based Micelles for Glutathione-Responsive Targeted Chemotherapy and Photodynamic Therapy.